Rick Gonzalez, AbbVie CEO (Pablo Martinez Monsivais/AP Images)

Ab­b­Vie makes sec­ond deal in a week, bet­ting $8.7B in cash on CNS biotech Cerev­el 

Ab­b­Vie said Wednes­day evening it plans to pay $8.7 bil­lion to ac­quire neu­ro­science drug­mak­er Cerev­el Ther­a­peu­tics in a deal that comes …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.